Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/g, the generic version of Mycolog-II (Nystatin and triamcinolone acetonide) Cream, 100,000 units/g, 0.1%, of Delcor Asset Corporation (which is no longer being marketed in the United States).
According to IMS Health sales data for the 12 month period ending August 2016, the Mycolog-II (nystatin and triamcinolone acetonide) Cream, 100,000 units/g, 0.1% market' achieved annual sales of approximately USD 120.9 million.
Shares of the company gained Rs 3.65, or 0.39%, to trade at Rs 937.10. The total volume of shares traded was 0 at the BSE (9.05 a.m., Tuesday).